Abstract
Animal behavioural profiles are commonly employed to investigate new therapeutic agents to treat anxiety disorders as well as to investigate the mechanism of action of anxiolytic drugs. However, many clinically important symptoms of anxiety can not be modelled directly in animals. Human models of anxiety should bridge between animal models and anxiety disorders. Experimental anxiety states in humans can be induced by either pharmacological means such as CO2 inhalation or psychological means such as aversive conditioning of skin conductance responses to tones. Investigation of these models may contribute to a better understanding of anxiety disorders, both from a biological and behavioural point of view. In a comprehensive review existing models of human experimental anxiety states are summarized and validity is discussed.
Keywords: Anxiety, model, anxiolytic, drug development, humans
Current Neuropharmacology
Title: Modelling Anxiety in Humans for Drug Development
Volume: 5 Issue: 1
Author(s): Martin Siepmann and Peter Joraschky
Affiliation:
Keywords: Anxiety, model, anxiolytic, drug development, humans
Abstract: Animal behavioural profiles are commonly employed to investigate new therapeutic agents to treat anxiety disorders as well as to investigate the mechanism of action of anxiolytic drugs. However, many clinically important symptoms of anxiety can not be modelled directly in animals. Human models of anxiety should bridge between animal models and anxiety disorders. Experimental anxiety states in humans can be induced by either pharmacological means such as CO2 inhalation or psychological means such as aversive conditioning of skin conductance responses to tones. Investigation of these models may contribute to a better understanding of anxiety disorders, both from a biological and behavioural point of view. In a comprehensive review existing models of human experimental anxiety states are summarized and validity is discussed.
Export Options
About this article
Cite this article as:
Siepmann Martin and Joraschky Peter, Modelling Anxiety in Humans for Drug Development, Current Neuropharmacology 2007; 5 (1) . https://dx.doi.org/10.2174/157015907780077114
DOI https://dx.doi.org/10.2174/157015907780077114 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potassium Channels in Peripheral Pain Pathways: Expression, Function and Therapeutic Potential
Current Neuropharmacology The Vanilloid Agonist Resiniferatoxin for Interventional-Based Pain Control
Current Topics in Medicinal Chemistry Neurotoxicity of Insecticides
Current Medicinal Chemistry Specific Roles of NMDA Receptor Subunits in Mental Disorders
Current Molecular Medicine N-Acetylcysteine for the Treatment of Obsessive-Compulsive Disorder
Current Psychiatry Reviews Adiposity and the Gut - The Role of Gut Hormones
Current Nutrition & Food Science Network Medicine and High Throughput Screening
Current Drug Discovery Technologies Activity-Dependent Neurorehabilitation Beyond Physical Trainings: “Mental Exercise” Through Mirror Neuron Activation
CNS & Neurological Disorders - Drug Targets Stress as a Pathophysiological Factor in Functional Somatic Syndromes
Current Psychiatry Reviews Different Food Odors Control Brain Connectivity in Impulsive Children
CNS & Neurological Disorders - Drug Targets New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)
Current Medicinal Chemistry Genetic Association Analysis of NOS3 and Methamphetamine-Induced Psychosis Among Japanese
Current Neuropharmacology Leber's Hereditary Optic Neuropathy: Novel Views and Persisting Challenges
CNS & Neurological Disorders - Drug Targets Congenital Cytomegalovirus Infection: An Overview
Infectious Disorders - Drug Targets On Some Physiological Aspects of Ethanol Repercussion on Neural and Cardiorenal Functions
Central Nervous System Agents in Medicinal Chemistry Oligodendrocyte Development and Myelination in Neurodevelopment: Molecular Mechanisms in Health and Disease
Current Pharmaceutical Design One-year Outcome of Shanghai Mild Cognitive Impairment Cohort Study
Current Alzheimer Research Myofascial Temporomandibular Disorder
Current Rheumatology Reviews Glutamate Signaling in Synaptogenesis and NMDA Receptors as Potential Therapeutic Targets for Psychiatric Disorders
Current Molecular Medicine Role of the Central Cholinergic System in the Therapeutics of Schizophrenia
Current Neuropharmacology